Impact BioMedical, INC. (IBO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.04M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 62.00K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.04M | (m) | (m) | (m) | $62.00K | (m) |
| 2026-03-31 | (m) | $1.69M | $20.00K | (m) | (m) | $63.00K | (m) |
| 2025-12-31 | (m) | $1.16M | $3.00K | (m) | $5.00K | $63.00K | (m) |
| 2025-09-30 | (m) | $23.79M | $12.00K | (m) | $15.00K | $485.00K | (m) |
| 2025-06-30 | (m) | $23.17M | $624.00K | (m) | (m) | $486.00K | (m) |
| 2025-03-31 | (m) | $9.97M | $1.32M | (m) | $4.00K | $489.00K | (m) |
| 2024-12-31 | (m) | $9.79M | $2.00M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.14M | $2.67M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $14.50M | $2.00K | (m) | $128.00K | (m) | (m) |
| 2024-03-31 | (m) | $13.86M | $2.00K | (m) | $128.00K | (m) | (m) |
| 2023-12-31 | (m) | $13.14M | $1.00K | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $12.27M | $201.00K | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $12.05M | $3.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $10.59M | $2.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |